Teva and MedinCell Receive the US FDA’s Approval of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia
Shots:
- The US FDA has approved Uzedy (risperidone) extended-release injectable suspension for the treatment of adults with schizophrenia
- The approval was based on the results from the 2 P-III study (RISE) & (SHINE) evaluating the efficacy of risperidone extended-release injectable suspension for SC use in 544 & 336 patients aged 13-65yrs. with schizophrenia. The results showed that the patients treated with Uzedy achieved a ~80% reduction in risk of schizophrenia relapse over PBO
- Uzedy, the first SC, long-acting formulation of risperidone that has been developed using SteadyTeq (copolymer technology) to MedinCell that controls the steady release of risperidone
Ref: Businesswire | Image: Teva
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
